Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Equity (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Return on Equity over the past 12 years, most recently at 0.56% for Q4 2025.

  • Quarterly results put Return on Equity at 0.56% for Q4 2025, down 17.0% from a year ago — trailing twelve months through Dec 2025 was 0.56% (down 17.0% YoY), and the annual figure for FY2025 was 0.49%, changed 0.0%.
  • Return on Equity for Q4 2025 was 0.56% at Viridian Therapeutics, Inc.\DE, up from 0.59% in the prior quarter.
  • Over the last five years, Return on Equity for VRDN hit a ceiling of 0.32% in Q4 2022 and a floor of 1.3% in Q2 2021.
  • Median Return on Equity over the past 5 years was 0.52% (2022), compared with a mean of 0.59%.
  • Biggest five-year swings in Return on Equity: surged 117bps in 2021 and later tumbled -33bps in 2023.
  • Viridian Therapeutics, Inc.\DE's Return on Equity stood at 0.41% in 2021, then increased by 20bps to 0.32% in 2022, then crashed by -103bps to 0.65% in 2023, then surged by 40bps to 0.39% in 2024, then tumbled by -42bps to 0.56% in 2025.
  • The last three reported values for Return on Equity were 0.56% (Q4 2025), 0.59% (Q3 2025), and 0.61% (Q2 2025) per Business Quant data.